Baidu
map

JCI:治疗深静脉血栓的新方法

2014-07-07 佚名 不详

项研究发现去除酶因子ⅩⅢ,能降低血凝块中红细胞的数量,导致凝块的大小减少了50%。这一发现发表在Journal of Clinical Investigatio杂志上,对深静脉血栓(DVT)高风险的人有重大影响。 论文作者Alisa Wolberg博士表示:如果我们能够利用这一发现,以减少血液凝块的大小,这将意味着一个全新的方法来治疗血栓。我们认为降低ⅩⅢ因子活性可帮助一大批人,包括那些无法

项研究发现去除酶因子ⅩⅢ,能降低血凝块中红细胞的数量,导致凝块的大小减少了50%。这一发现发表在Journal of Clinical Investigatio杂志上,对深静脉血栓(DVT)高风险的人有重大影响。

论文作者Alisa Wolberg博士表示:如果我们能够利用这一发现,以减少血液凝块的大小,这将意味着一个全新的方法来治疗血栓。我们认为降低ⅩⅢ因子活性可帮助一大批人,包括那些无法利用现有的“血液稀释”药物的人。血液凝结能力对我们的健康至关重要,通过阻止出血,使伤口愈合,血栓让我们避免受伤流血而死。但在错误的情况下,凝块可能会造成显著健康危害。

深静脉血栓患者,血管内形成血栓,通常导致两腿瘫痪,阻碍血液的流动,从而导致疼痛、肿胀。许多患者经常服用血液稀释药物如华法林,但这扼杀了身体生成纤维蛋白的能力。这些药物提高出血过多的危险,可引起副作用,并且不适合于所有的患者。

我们需要的是一种药物降低了形成大的血凝块的风险,但仍然可以让你拥有形成血块的能力(当出血的时候),Wolberg说:我们已经发现可能使人们有可能取得这种平衡的生物途径。在利用老鼠和人类的血液实验中,研究人员研究了ⅩⅢ因子蛋白在血块形成中的作用。令他们吃惊的是,他们发现,不能产生ⅩⅢ因子的小鼠虽然也能形成血凝块,但大小是正常小鼠形成血凝块的一半大小。

然后,研究发现,大小差异实际上是由于血块中红细胞的数量减少导致的。因子XIII似乎在形成凝块中,帮助纤维蛋白基质保持其完整性起到了至关重要的作用。正常情况下,血纤蛋白基质在凝块内部和周围形成了一个强有力的网格,捕获红细胞。无因子XIII后,一些红血细胞被挤压出来,导致一个更小的血块。不同于现有的以减少纤维蛋白药物,也许将来一种降低凝血因子XIII药物可能会削减人体产生大量的,危险的血块能力,但不牺牲生成小的,有利于血栓形成的血块的能力。

原始出处

Aleman MM, Byrnes JR, Wang JG, Tran R, Lam WA, Di Paola J, Mackman N, Degen JL, Flick MJ, Wolberg AS.Factor XIII activity mediates red blood cell retention in venous thrombi.J Clin Invest. 2014 Jul 1.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2188407, encodeId=4802218840ee9, content=静脉血栓, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7cb9082948, createdName=ms2000001026077378, createdTime=Tue Feb 20 22:49:41 CST 2024, time=2024-02-20, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=30152, encodeId=9cd3301521d, content=看看下, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Wed Jul 01 20:38:00 CST 2015, time=2015-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903066, encodeId=5d56190306610, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun May 03 01:08:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697221, encodeId=cc1a169e22133, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Aug 05 01:08:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955201, encodeId=2282195520121, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Fri Aug 08 11:08:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981984, encodeId=996a1981984ff, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri Aug 22 03:08:00 CST 2014, time=2014-08-22, status=1, ipAttribution=)]
    2024-02-20 ms2000001026077378 来自山东省

    静脉血栓

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2188407, encodeId=4802218840ee9, content=静脉血栓, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7cb9082948, createdName=ms2000001026077378, createdTime=Tue Feb 20 22:49:41 CST 2024, time=2024-02-20, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=30152, encodeId=9cd3301521d, content=看看下, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Wed Jul 01 20:38:00 CST 2015, time=2015-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903066, encodeId=5d56190306610, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun May 03 01:08:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697221, encodeId=cc1a169e22133, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Aug 05 01:08:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955201, encodeId=2282195520121, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Fri Aug 08 11:08:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981984, encodeId=996a1981984ff, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri Aug 22 03:08:00 CST 2014, time=2014-08-22, status=1, ipAttribution=)]
    2015-07-01 owlhealth

    看看下

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2188407, encodeId=4802218840ee9, content=静脉血栓, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7cb9082948, createdName=ms2000001026077378, createdTime=Tue Feb 20 22:49:41 CST 2024, time=2024-02-20, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=30152, encodeId=9cd3301521d, content=看看下, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Wed Jul 01 20:38:00 CST 2015, time=2015-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903066, encodeId=5d56190306610, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun May 03 01:08:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697221, encodeId=cc1a169e22133, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Aug 05 01:08:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955201, encodeId=2282195520121, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Fri Aug 08 11:08:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981984, encodeId=996a1981984ff, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri Aug 22 03:08:00 CST 2014, time=2014-08-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2188407, encodeId=4802218840ee9, content=静脉血栓, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7cb9082948, createdName=ms2000001026077378, createdTime=Tue Feb 20 22:49:41 CST 2024, time=2024-02-20, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=30152, encodeId=9cd3301521d, content=看看下, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Wed Jul 01 20:38:00 CST 2015, time=2015-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903066, encodeId=5d56190306610, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun May 03 01:08:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697221, encodeId=cc1a169e22133, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Aug 05 01:08:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955201, encodeId=2282195520121, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Fri Aug 08 11:08:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981984, encodeId=996a1981984ff, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri Aug 22 03:08:00 CST 2014, time=2014-08-22, status=1, ipAttribution=)]
    2014-08-05 fusion
  5. [GetPortalCommentsPageByObjectIdResponse(id=2188407, encodeId=4802218840ee9, content=静脉血栓, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7cb9082948, createdName=ms2000001026077378, createdTime=Tue Feb 20 22:49:41 CST 2024, time=2024-02-20, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=30152, encodeId=9cd3301521d, content=看看下, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Wed Jul 01 20:38:00 CST 2015, time=2015-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903066, encodeId=5d56190306610, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun May 03 01:08:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697221, encodeId=cc1a169e22133, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Aug 05 01:08:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955201, encodeId=2282195520121, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Fri Aug 08 11:08:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981984, encodeId=996a1981984ff, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri Aug 22 03:08:00 CST 2014, time=2014-08-22, status=1, ipAttribution=)]
    2014-08-08 xue8602
  6. [GetPortalCommentsPageByObjectIdResponse(id=2188407, encodeId=4802218840ee9, content=静脉血栓, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c7cb9082948, createdName=ms2000001026077378, createdTime=Tue Feb 20 22:49:41 CST 2024, time=2024-02-20, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=30152, encodeId=9cd3301521d, content=看看下, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Wed Jul 01 20:38:00 CST 2015, time=2015-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903066, encodeId=5d56190306610, content=<a href='/topic/show?id=e1b0583884b' target=_blank style='color:#2F92EE;'>#新方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58388, encryptionId=e1b0583884b, topicName=新方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun May 03 01:08:00 CST 2015, time=2015-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697221, encodeId=cc1a169e22133, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Tue Aug 05 01:08:00 CST 2014, time=2014-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955201, encodeId=2282195520121, content=<a href='/topic/show?id=0aeb991e44c' target=_blank style='color:#2F92EE;'>#静脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99174, encryptionId=0aeb991e44c, topicName=静脉血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Fri Aug 08 11:08:00 CST 2014, time=2014-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981984, encodeId=996a1981984ff, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Fri Aug 22 03:08:00 CST 2014, time=2014-08-22, status=1, ipAttribution=)]

相关资讯

ICU患者深静脉血栓形成预防指南2009

ICU患者深静脉血栓形成预防指南2009.pdf

Lancet:间歇充气加压能有效降低脑卒中患者深静脉血栓发生的风险

深静脉栓塞是造成住院患者死亡和发病的一种常见的但可以避免的原因,在脑卒中患者中也是如此。在接受手术的患者中,间歇加压充气(IPC)能降低深静脉血栓发生的风险,但是目前还没有确实可靠的证据可以证明IPC对脑卒中患者具有同样的疗效。为了评估IPC能否有效降低脑卒中患者深静脉血栓发生的风险,来自CLOTS研究协作组的研究者们设计了相关研究,并将其研究结果发表在The Lancet 5月的在线期刊上。

美国网站推出“心脏年龄计算器”

心脏就像一个高速运转的发动机,如果按一个人心脏平均每分钟跳70次、寿命70岁计算的话,心脏每天跳动10万次左右,一生要跳近26亿次。这个身体里最繁忙的器官需要我们细心呵护,但遗憾的是,人们不健康的生活习惯已经让它提前衰老。美国“心脏年龄”网站近日推出一项测试,从体重、运动、饮食、吸烟、家族史等多方面进行评估,测算出你的心脏年龄和实际年龄是否同步。 《生命时报》记者对此向北京中医药大学

ACCP与AAOS指南之争:骨科大手术深静脉血栓栓塞预防指南

    骨科大手术后并发下肢深静脉血栓栓塞(DVT)、肺栓塞(PE),甚至发生致命的PE已越来越受到人们的关注。美国胸科医师协会(ACCP)早在1986 年发表了第一部有关静脉血栓栓塞(VTE)临床指南,后经更新,至2008年推出了第八版指南,对骨科大手术后VTE、DVT、PE预防治疗提出了更积极、更全面建议。美国骨科医师协会(AAOS)2007年综合42篇相关文献结

NEJM:口服直接Xa因子抑制剂治疗急性症状性肺栓塞患者

  背景  研究已显示,固定剂量利伐沙班(一种口服Ⅹa 因子抑制剂)方案治疗深静脉血栓形成的疗效与标准抗凝疗法相同,且不需要实验室监测,这一方法也可能简化肺栓塞的治疗。   方法  在一项纳入4832 例患急性症状性肺栓塞、伴有或不伴有深静脉血栓形成患者的随机、开放标签、事件驱动的非劣效试验中,我们对利伐沙班(15 mg,2次/日,3周,随后为20 mg,1次/日)与依诺肝素

FDA批准利伐沙班用于深静脉血栓及肺栓塞治疗

近日,FDA批准利伐沙班(商品名拜瑞妥)用于治疗急性深静脉血栓(DVT)、肺栓塞以及预防其复发。该药物除了可以用于预防非瓣膜性房颤患者发生血栓及卒中外,还能预防手术后的急性深静脉血栓。FDA血液及肿瘤药物评价和研究中心主任Richard Pazdur说,拜瑞妥是继华法林获批60年后,第一个被批准的口服抗凝血药物,用于治疗并降低血栓的复发。该药获批基于三次临床试验,共计9,478个受试者,这些患者随

Baidu
map
Baidu
map
Baidu
map